Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded at StockNews.com

StockNews.com upgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP) from a sell rating to a hold rating in a research report released on Monday morning.

Oramed Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ ORMP opened at $2.34 on Monday. The company’s fifty day simple moving average is $2.38 and its 200 day simple moving average is $2.41. Oramed Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $3.67. The firm has a market cap of $94.33 million, a PE ratio of 21.27 and a beta of 1.67.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of large investors have recently modified their holdings of ORMP. Marquette Asset Management LLC acquired a new position in Oramed Pharmaceuticals during the 4th quarter valued at about $81,000. XTX Topco Ltd increased its holdings in Oramed Pharmaceuticals by 59.7% in the 3rd quarter. XTX Topco Ltd now owns 24,716 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 9,242 shares during the last quarter. Murchinson Ltd. raised its position in shares of Oramed Pharmaceuticals by 0.5% in the third quarter. Murchinson Ltd. now owns 1,708,879 shares of the biotechnology company’s stock valued at $4,170,000 after purchasing an additional 8,889 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Oramed Pharmaceuticals during the 3rd quarter valued at $272,000. Finally, BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after purchasing an additional 837,153 shares during the period. 12.73% of the stock is currently owned by institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.